Les progrès dans le traitement des cancers de la thyroide à l'ère des thérapies ciblées moléculaires

G. Malouf, E. Baudin, J. C. Soria, M. Schlumberger

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    5 Citations (Scopus)

    Résumé

    During last decade, many progresses have been made in the understanding of thyroid cancer molecular biology. This knowledge led to the development of novel targeted therapy in iodine-resistant patients. However, the management of patients remains complex because of the broad spectrum of clinical presentation of thyroid cancers, differences in their natural histories and the lack of data about randomized trials. Angiogenesis inhibitors (sorafenib, motesanib, axitinib and vandetanib) have shown promising activity in differentiated thyroid cancer. Vandetanib, an inhibitor of RET and VEGFR tyrosine-kinases, is promising in medullary thyroid cancers. Preliminary results of these trials are discussed in this review.

    Titre traduit de la contributionAdvances in the treatment of thyroid cancer in the era of molecularly targeted therapies
    langue originaleFrançais
    Pages (de - à)95-101
    Nombre de pages7
    journalBulletin du Cancer
    Volume96
    Numéro de publication1
    Les DOIs
    étatPublié - 1 janv. 2009

    mots-clés

    • Angiogenesis inhibitors
    • Medullary thyroid cancers
    • Molecular biology
    • Targeted therapies
    • Thyroid cancers
    • Tyrosine kinases inhibitors

    Contient cette citation